scholarly journals LIPID PROFILE AND ALBUMINURIA RELATIONSHIP WITH NUCLEOTIDE POLYMORPHISM –204 А > С [rs 3808607] OF СУР7А1 GENE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION

2018 ◽  
pp. 37-43
Author(s):  
N. Demikhova ◽  
O. Chernatska ◽  
T. S. Mazur ◽  
S. I. Bokova ◽  
T. M. Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Lipid Profile ◽  
Third Stage ◽  
Major Allele ◽  
Definition Of ◽  
The Relationship

The aim of our study is the definition of diabetic nephropathy peculiarities and the relationship between albuminuria and indicators of lipid profile, genotype variants of СУР7А1 for patients with type 2 diabetes mellitus and the third stage of arterial hypertension. Patients are divided into 3 groups. The patients of the I group are defined with normoalbuminuria, microalbuminuria – in the ІІ, macroalbuminuria – in the III. The definition of albumin to creatinin ratio is the most precise, but a more expensive method. The SNP –204 А > С [rs 3808607] of СУР7А1 promotor section is defined. Homozygotes by major allele with AA genotype have the less level of albuminuria, aterogenic lipoproteids, general cholesterol, triglycerides and the biggest level of antiaterogenic lipoproteids in comparison with patients with AC and CC genotype. The genotype CC is the worst in the terms of prognosis because the level of albuminuria, aterogenic lipoproteids, general cholesterol, triglycerides and lipoproteids with low density is increased but the level of lipoproteids with high density is decreased.

scholarly journals LIPID PROFILE AND ALBUMINURIA RELATIONSHIP WITH NUCLEOTIDE POLYMORPHISM –204 А > С [rs 3808607] OF СУР7А1 GENE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION

2018 ◽  
pp. 37-43
Author(s):  
N. Demikhova ◽  
O. Chernatska ◽  
T. S. Mazur ◽  
S. I. Bokova ◽  
T. M. Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Lipid Profile ◽  
Third Stage ◽  
Major Allele ◽  
Definition Of ◽  
The Relationship

The aim of our study is the definition of diabetic nephropathy peculiarities and the relationship between albuminuria and indicators of lipid profile, genotype variants of СУР7А1 for patients with type 2 diabetes mellitus and the third stage of arterial hypertension. Patients are divided into 3 groups. The patients of the I group are defined with normoalbuminuria, microalbuminuria – in the ІІ, macroalbuminuria – in the III. The definition of albumin to creatinin ratio is the most precise, but a more expensive method. The SNP –204 А > С [rs 3808607] of СУР7А1 promotor section is defined. Homozygotes by major allele with AA genotype have the less level of albuminuria, aterogenic lipoproteids, general cholesterol, triglycerides and the biggest level of antiaterogenic lipoproteids in comparison with patients with AC and CC genotype. The genotype CC is the worst in the terms of prognosis because the level of albuminuria, aterogenic lipoproteids, general cholesterol, triglycerides and lipoproteids with low density is increased but the level of lipoproteids with high density is decreased.

scholarly journals Effectiveness of atorvastatin therapy in patients with arterial hypertension, diabetic nephropathy and diabetes mellitus type 2

2019 ◽  
pp. 105-110
Author(s):  
O. M. Chernatska ◽  
T. S. Mazur ◽  
N. V. Demikhova ◽  
O. M. Vlasenko ◽  
T. M. Rudenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Arterial Hypertension ◽  
Lipid Profile ◽  
Cardiovascular Complications ◽  
Actual Problem ◽  
Type 2 Dm

The actual problem of internal medicine is the managemen of patients with comorbid pathology. Arterial hypertension (AH) is determined in about quarter of the population in the world. Moreover, the coexistence of AH and type 2 diabetes mellitus (DM) connected with the increased risk of cardiovascular complications (CVC) compared with patients with AH. In principle dyslipidemia is the common link between AH and type 2 DM, which need the correction. No doubt that reduction of atherogenic and increase of anti atherogenic lipoproteins is necessary for persons with comorbid pathology. The objective of our study was the assessment of atorvastatin treatment in patients with AH, diabetic nephropathy and type 2 DM. We obtained 96 patients with AH, diabetic nephropathy and type 2 DM (І group), 25 persons with AH (ІІ group), 15 conditionally healthy individuals. Persons had CVC in the past. For patients from the І and ІІ group CVC were defined accordingly (4,97 ± 0,20) years and (4,10 ± 0,05) years ago (P = 0,0291). The duration of AH is (8,1 ± 0,2) years for the І group and (8,90 ± 0,13) years for the ІІ group. The levels of lipid profile spectrum were determined according to the methods of W. T. Friedewald. The results of investigation were analyzed with the help of Microsoft Excel 2016. Correction of lipid profile spectrum is the important part of multipurpose treatment for persons with coexistent pathology. All patients were treated by atorvastatin (10−40 mg/day) during 6 months in a complex therapy. The target levels of general cholesterol during 6 months were presented in 30 persons (31.91 %), low density lipoproteids – in 10 persons (10.64 %), high density lipoproteids – in 26 persons (27.66 %), triglycerides – in 34 persons (36.17 %) among patients with AH, diabetic nephropathy and type 2 DM. In conclusion, it is advisable to prescribe atorvastatin (10–40 mg/day) for correction of dyslipidemia, reduction of proatherogenic orientation, prevention of atherosclerotic process manifestation and cardiovascular complications in patients with AH with diabetic nephropathy and type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document